AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
10.8 C
New York
Friday, October 23, 2026

Tag: pharmaceuticals

newsFORsourcecompanycontentinformation1releasesmarket

Willog Partners with Republic of Korea Army to Modernize Military Logistics with AI and IoT Solutions

SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- Willog, a leading provider of IoT and AI-powered supply chain intelligence solutions, today announced the signing of...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment...

Hydrofluoric Acid Market worth $5.10 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 12, 2025 /PRNewswire/ -- The report 'Hydrofluoric Acid Market by Grade , Application, and Region (Asia Pacific, North America, Europe,...

Hydrofluoric Acid Market worth $5.10 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 12, 2025 /PRNewswire/ -- The report 'Hydrofluoric Acid Market by Grade , Application, and Region (Asia Pacific, North America, Europe,...

Cardinal Health announces the addition of Solaris Health, the country’s leading urology MSO, to The Specialty Alliance

Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty AllianceJoins with recent urology acquisitions to bolster The Specialty Alliance's leadership in...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License...

FOOD & HOSPITALITY MALAYSIA 2025 CULTIVATES FUTURE-READY INDUSTRY SOLUTIONS

Malaysia's premier food and hospitality trade show returns in September with new features, alongside FutureFWD Conference by Saladplate KUALA LUMPUR, Malaysia, Aug. 12, 2025 /PRNewswire/...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceuticals

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers